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Abstract
Dengue virus (DENV) is a mosquito-borne flavivirus that causes serious human disease
and mortality worldwide. There is no specific antiviral therapy or vaccine for DENV infection.
Alterations in gene expression during DENV infection of the mosquito and the impact of
these changes on virus infection are important events to investigate in hopes of creating
new treatments and vaccines. We previously identified 203 genes that were5-fold differ-
entially upregulated during flavivirus infection of the mosquito. Here, we examined the
impact of silencing 100 of the most highly upregulated gene targets on DENV infection in
its mosquito vector. We identified 20 genes that reduced DENV infection by at least 60%
when silenced. We focused on one gene, a putative cysteine rich venom protein (SeqID
AAEL000379; CRVP379), whose silencing significantly reduced DENV infection in Aedes
aegypti cells. Here, we examine the requirement for CRVP379 during DENV infection of the
mosquito and investigate the mechanisms surrounding this phenomenon. We also show
that blocking CRVP379 protein with either RNAi or specific antisera inhibits DENV infection
in Aedes aegypti. This work identifies a novel mosquito gene target for controlling DENV
infection in mosquitoes that may also be used to develop broad preventative and therapeu-
tic measures for multiple flaviviruses.
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Author Summary
Dengue virus (DENV) is responsible for serious human disease worldwide and the World
Health Organization estimates that over 2 billion people are at risk for disease. There are
no vaccines or specific antiviral medications currently available for DENV infection.
DENV is transmitted to humans by infected mosquitoes during feeding and probing. By
examining the effects of virus infection on gene expression, and interactions between virus
and vector, we may be able to find new targets for prevention and treatment. Here we look
at a mosquito protein, CRVP379, whose gene expression was highly increased during
DENV infection in mosquitoes. We show a requirement for CRVP379 during DENV
infection in the mosquito and a correlation between the levels of CRVP379 and levels of
infection. Our results indicate that the protein may be acting with a putative DENV recep-
tor in the mosquito, prohibitin protein. These data also suggest that blocking CRVP379
function may be used to block DENV infection in the mosquito.
Introduction
Dengue virus (DENV) is the most important arbovirus in tropical areas leading to substantial
pediatric morbidity and mortality worldwide [1–6]. DENV is transmitted to humans via the
bite of an infected mosquito of the Aedes spp. Infection with DENV in humans can result in
dengue fever (DF), dengue shock symptom (DSS) and dengue hemorrhagic fever (DHF), the
latter two that can lead to severe disease and death. There are no specific antivirals or approved
vaccines for use in DENV treatment or prevention [4,7–9]. Current dengue control methods
rely mostly on activities to reduce vector population [10,11]. The increase in number of cases
despite vector control indicates that these strategies are not as effective as expected, and that
new tools need be developed to alleviate disease burden in endemic areas [12–14].
During the last five decades, much effort has been invested in the development of vaccines
against DENV [15–23]. One of the obstacles in dengue vaccine development is the potential
risk of severe disease mediated by the presence of sub-neutralizing antibodies against virus par-
ticles. These antibodies can predispose an individual to severe disease through a phenomenon
called antibody-dependent enhancement (ADE), where the virus can infect cells via FcR in
mononuclear cells [8,9,24–28]. Traditional vaccine approaches have included live attenuated
viruses, recombinant subunits, virus-like particles and plasmid or viral vectors. There are live
attenuated and chimeric DENV vaccines that have gone into clinical trials but none have
proven to provide complete and lasting protection against all four DENV serotypes [21,29].
An attractive complement to traditional vaccines is to induce an immune response in the
vertebrate host (infected or non-infected) that will block virus infection of the mosquito vec-
tors. This would successfully interrupt transmission by inducing antibody responses against
non-viral antigens [30]. These type of vaccines are called transmission-blocking vaccines
(TBV), since they aim to interfere with pathogen development within the vector, thereby block-
ing transmission to human hosts [31]. The majority of TBVs designed to inhibit malaria infec-
tion are based on the mammalian immune response to pathogen proteins [31]. Another
category of TBVs in development are based on arthropod molecules able to reduce pathogen
infection in vector tissues [32]. For arboviruses, vector molecules able to interact directly with
the pathogen (i.e. ligands/receptors) are highly suitable candidates for blocking transmission
[33,34].
The main global transmission vector for DENV is Ae. aegypti. Extensive research has shown
that DENV infection of Ae. aegypti induces many varied changes in gene expression [35–44].
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Our hypothesis is that genes upregulated during DENV infection are required for virus survival
or are related with defense against infection [37]. Consequently, a better understanding of the
role of mosquito proteins regulated by DENV infection will reveal important insights into
DENV biology and transmission as well as be helpful to the design of an effective TBV against
DENV. For example, antibodies directed against mosquito molecules involved in steps of the
pathogen life cycle are promising candidates for TBV. In addition, a recent study demonstrated
that antibodies against a mosquito C-type lectin, mosGCTL1, effectively interrupts the infec-
tion of Ae. aegyptimosquitoes with DENV [34]. Other proteins which genes are unregulated
upon infection also show promising capacity of interrupting infection since they are considered
important for the microorganism survival. One of these proteins is the tick histamine release
factor (tHRF) from Ixodes scapularis upregulated during Borrelia burgdorferi infection. Previ-
ous work showed that expression of tHRF is associated with the tick blood feeding and that the
silencing its gene by RNA interference or antibodies not only effectively impairs tick feeding
but subsecuently decreases B. burgdorferi burden [45].
Using comprehensive microarray analysis to identify key alterations in the Ae. aegypti tran-
scriptome during flavivirus infection, we previously identified 203 mosquito genes that were
up- and 202 genes that were down-regulated during infection [35]. Comparative analysis
revealed that at least 15 of these genes had differential expression during infection with DENV,
Yellow fever (YFV) and West Nile virus (WNV) [35]. One of these conserved, up-regulated
genes was a putative cysteine-rich venom protein (AAEL000379), which we named CRVP379.
Cysteine-rich venom proteins (CRVPs) are expressed in multiple mosquito tissues including
the salivary glands [37,46,47]. Examples of mosquito CRVPs include an An. stephensi peptide
annotated as salivary-secreted serine protease inhibitor [48] and a putative cysteine-rich prote-
ase inhibitor found in the sialotranscriptome of adult female Culex quinquefasciatus [49]. The
specific role of these proteins in mosquitoes remains unknown [46,47].
Here, we describe a requirement for CRVP379 during DENV infection in mosquito cells
and live mosquitoes, including a direct correlation between the amount of CRVP379 expressed
and the level of DENV infection. We demonstrate the importance of an interaction between
CRVP379 and prohibitin, a putative DENV receptor protein in mosquitoes. We also assess the
tissue-specific expression of CRVP379 during DENV infection. Finally, we use both RNAi and
specific antibody to demonstrate that blocking CRVP379 results in inhibition of DENV infec-
tion in Ae. aegypti. These results further our understanding of DENV pathogenesis in the mos-
quito vector and highlight a potential target protein for the creation of a DENV TBV to break
the host-vector transmission cycle.
Results
Silencing virally up-regulated genes alters DENV infection in mosquito
cells
We previously used microarray analysis to identify a number of Ae. aegypti genes that were sig-
nificantly up-regulated during infection with DENV and other selected flaviviruses [35]. These
genes are likely required for flaviviral infection of Ae. aegypti or are part of the mosquito
immune response to viral infection. To elucidate the role of these genes and their correspond-
ing proteins, we reduced gene expression through RNAi knockdown and analyzed the effect on
viral infection. We designed siRNA against 100 genes that were significantly up-regulated dur-
ing DENV infection of Ae. aegypti (S1 Fig). The siRNA was used to silence these genes in an
Ae. aegypti cell line, Aag2, and the resulting effects on DENV infection were examined. Cells
were infected with DENV 72h after siRNA transfection and analyzed for infection using
qRT-PCR 24h post-infection. We found that gene silencing both increased and decreased
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DENV infection, as expected (S2 Fig). The silencing of 9 genes caused cytotoxicity beyond our
ability to accurately measure infection levels. Silencing approximately 55 individual genes
decreased DENV infection of the cells to below 60% of control infection (Fig 1A), which is
greater than 40% inhibition of infection. A number of these genes encode hypothetical proteins
for which the function is not known. Several of our target genes do have putative known func-
tions, including a cytochrome P450 (AAEL009762), histone H3 (AAEL003685) and a cysteine-
rich venom protein (AAEL000379).
The cysteine-rich venom protein (CRVP), which we will call CRVP379, was a particularly
interesting target. CRVP proteins are known to contain a trypsin inhibitor-like (TIL) domain,
which indicates that the CRVP379 protein could be a serine protease inhibitor. Both serine
proteases and their inhibitors are known to be involved in DENV infection and pathogenesis
in the mosquito vector as well as in mammals [50–55]. The expression levels of 19 mosquito
CRVP genes were examined during flavivirus infection with the previous microarray analysis.
CRVP379 was the only CRVP significantly up-regulated in Ae. aegypti during infection with
any of the 3 prototypic flavivirus infections, including DENV, West Nile virus (WNV) and Yel-
low Fever virus (YFV), at all timepoints tested (Table 1) [35]. In addition, the 19 CRVP genes
that we looked at in our microarray actually have very low sequence identify at the amino acid
level (S3 Fig). This indicates that they may not have identical or even similar functions, though
they are grouped in a protein family due to the presence of multiple cysteines and a TIL
domain. Therefore, we decided to assess the role of CRVP379 in DENV infection of the mos-
quito vector in greater detail.
DENV infection requires CRVP379 in mosquito cells
Looking at gene expression over time in DENV-infected Aag2 cells, we found that CRVP379
expression increased more than 800-fold when compared to mock-infected cells (Fig 1B,
P<0.01). Since the gene was upregulated in mosquito cells during DENV infection, we wanted
to examine the phenotype during DENV infection with loss of function experiments. We used
RNA interference (RNAi) with siRNA to reduce CRVP379 gene expression. To confirm gene
knockdown, levels of CRVP379 were measured after siRNA transfection over time (Fig 1C),
and the expression levels remained below 10% at 72h post-transfection. To determine how the
reduction of CRVP379 altered DENV infection, we examined infection levels in Aag2 cells at
various timepoints from 1 to 24h post-infection during siRNA knockdown. Silencing
CRVP379 reduced DENV infection at all timepoints measured, as compared to infection in
control cells transfected with siRNA against GFP (Fig 1D). Interestingly, we noticed that levels
of CRVP379 were slightly elevated during DENV infection even during siRNA knockdown,
when compared to uninfected cells. This can be seen by looking at the fold change in CRVP379
expression in GFP siRNA-transfected cells as compared to CRVP379 siRNA-transfected cells
during DENV infection over time (Fig 1E). Together, these results indicated that the silencing
effects of RNAi on CRVP379 are slightly overcome by the gene upregulation during DENV
infection, but that infection levels still remained quite low when compared to cells with no
CRVP379 silencing.
Endogenous CRVP379 is sufficient for optimal DENV infection
Since we found that the presence of CRVP379 is required for DENV infection, we wanted to
test whether increasing CRVP379 levels would enhance infection levels. To do this, we cloned
the CRVP379 coding region into the insect expression vector pAc5.1/V5-His (Life Technolo-
gies, CA), resulting in pAcCRVP379 vector. This expression vector was transfected into an Ae.
aegyptimosquito cell line, Aag2, and the cells were subsequently infected with DENV. A vector
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 4 / 23
Fig 1. Silencing select virally-up-regulated genes reduces DENV infection in mosquito cells. A. The mosquito genes listed in S1 Fig were knocked
down in Aag2 cells using RNAi and the effects on DENV infection were analyzed. The genes that reduced infection below 60% of control are shown. Aag2
cells were infected with DENV (MOI of 1.0) 72 h post-knockdown and analyzed for infection by qRT-PCR 24h post-infection. Data is displayed as percent
control infection (using scrambled siRNA). Both DENV infection and qRT-PCR analysis were done in triplicate, data is pooled and error bars indicate
standard deviation. B. DENV infection increases CRVP379 in Aag2 cells over time. Aag2 cells were infected with DENV (MOI of 1.0) and infection was
measured using qRT-PCR analysis at the timepoints indicated. P<0.01. C. Expression of CRVP379 during RNAi knockdown. CRVP379 siRNA was
transfected into Aag2 cells and gene expression was analyzed by qRT-PCR. Samples were taken at 24, 48 and 72h post-knockdown. Expression after
DENV Requires CRVP for Mosquito Infection
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expressing GFP was transfected as a control into a separate group of DENV-infected cells.
Transfection levels as measured by GFP transfection are over 50%, which will give meaningful
results when looking at gene expression and effects on DENV infection (S4 Fig). At 48h post-
infection, levels of CRVP379 expression were measured by qRT-PCR. The expression levels of
CRVP379 were over 1000 times higher in the cells that were transfected with the CRVP379
plasmid (Fig 2A). We next infected the transfected cells with DENV at 48h post-transfection.
At 24 hpi, RNA was isolated and qRT-PCR done to measure DENV infection in the cells. We
found that the overexpression of CRVP379 did not increase DENV infection levels in the cells
(Fig 2B). This indicated that the endogenous levels of CRVP379 protein are sufficient and that
the virus has likely evolved to require only those amounts for optimum infection.
Acquisition of DENV requires CRVP379 in live mosquitoes
Since we found that CRVP379 was required for DENV infection of mosquito cells, we decided
to next look at the requirements for infection in live Ae. aegypti. To do this, we designed
dsRNA against the CRVP379 coding region and inoculated mosquitoes via intra-thoracic
injection. At days 2, 4 and 8 post-injection, we dissected out midgut tissues and measured levels
of CRVP379 expression by qRT-PCR analysis. Although knockdown was not achieved in all
transfection of GFP control siRNA is also indicated. D. Reduction of CRVP379 reduces DENV infection over time. Either siRNA against CRVP379 or GFP
was transfected into Aag2 cells and cells were infected with DENV (MOI of 1.0) at 72 h post-knockdown. Cells were analyzed for infection by qRT-PCR at the
timepoints indicated. E. DENV infection increases CRVP379 expression during siRNA knockdown. Either siRNA against CRVP379 or GFP was transfected
into Aag2 cells and cells were infected with DENV at 72 h post-knockdown. Gene expression was analyzed by qRT-PCR at the timepoints indicated. Data is
expressed as the fold change in CRVP379 expression in cells with GFP siRNA versus cells with CRVP379 siRNA during DENV infection. B-E. Data is pooled
from 6 separate experiments, error bars indicate standard deviation.
doi:10.1371/journal.ppat.1005202.g001
Table 1. Expression of CRVPs in Ae. aegypti during flavivirus infection.
SeqID YFV DENV2 WNV
AAEL000379 7.4, 6.6, 7.4 5.2, 3.1, 3.0 3.9, 3.1, 1.7
AAEL000353 -2.5, -4.4, -4.2 1.1, 1.5, 1.9 -1.5, -2.6, 1.2
AAEL005090 2.3, 4.3, 2.9 1.2, -1.4, 1.2 2.5, 1.2, 1.5
AAEL000363 1.1, -1.6, -2.3 1.3, 1.0, 1.9 -1.4, -1.2, 1.0
AAEL000317 1.2, -2.6, -4.7 1.4, 1.0, 1.9 -1.1, -2.1, -1.0
AAEL000369 -1.5, -1.7, -1.7 -1.0, 1.1, 2.5 -1.2, -1.6, 1.1
AAEL000333 -1.4, -4.1, -6.7 1.3, 1.1, 1.9 -1.4, -2.3, -1.1
AAEL000302 1.1, -2.2, -1.5 1.3, 2.3, 3.9 -1.2, -1.8, 1.2
AAEL000356 -2.6, -3.2, -2.4 -1.1, 1.0, 2.4 -1.7, -2.7, -1.2
AAEL002667 1.0, 2.1, 1.6 -1.6, 1.0, 1.0 -2.4, 1.9, 3.2
AAEL000361 1.6, -2.2, -1.5 1.9, 1.5, 1.0 1.1, -1.1, -1.3
AAEL005098 1.2, -1.1, -1.3 1.3, 1.0, 1.2 1.4, -1.3, -1.4
AAEL000351 -1.6, -2.3, -2.5 1.2, -1.1, 1.1 -1.1, -1.6, -1.2
AAEL000375 -2.2, -3.1, -1.5 1.7, 1.1, 2.3 -1.9, -2.3, 1.1
AAEL000374 -1.0, -1.8, -3.3 -2.2, -3.3, -1.8 -1.8, -2.5, -2.3
AAEL012194 -1.2, -1.6, -3.2 -2.5, -2.8, -1.6 -1.9, -2.4, -1.9
AAEL005487 1.5, 2.5, 2.8 1.3, 1.5, 1.4 2.2, 2.4, 1.5
AAEL013122 1.6, 1.3, 1.7 1.2, -1.2, -1.1 -1.1, 1.4, 1.5
AAEL000323 -1.2, -2.8, -1.2 1.1, 1.1, 1.2 1.5, 1.1, 2.5
Values are expressed as fold-change over mock infection at time points Day 1, 2, 7.
doi:10.1371/journal.ppat.1005202.t001
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tissues tested, a near-complete reduction of CRVP379 expression (over 95%) in midguts was
seen 70% of the time by day 8 (Fig 3-all panels). We next examined the effects of silencing
CRVP379 on DENV acquisition in the mosquito midgut. Mosquitoes were again injected with
dsRNA against CRVP379 or a control dsRNA against GFP protein. At day 4 post-injection,
mosquitoes were infected with DENV by blood feeding using a hemotek apparatus. At day 4
post-infection, midgut tissues were dissected out and analyzed for both CRVP379 expression
and DENV infection by qRT-PCR. Since not all midgut tissues had reduction in CRVP379
expression, we analyzed each midgut individually in order to examine the effects on DENV
infection in midguts that did have reduced CRVP379. The levels of CRVP379 in the selected
midguts are shown in Fig 3A. In the midguts that had reduced CRVP379 expression, DENV
infection was almost completely inhibited, as compared to infection in control mosquito mid-
guts (Fig 3B, P<0.01). We also analyzed the data after adding back in the midguts that did not
have sufficient gene knock down and looked at levels of DENV infection. Fig 3C shows the lev-
els of CRVP379 in these midguts. Interestingly, in midgut tissues where CRVP379 was not
knocked down, DENV infection was comparable to levels in the GFP dsRNA-injected mosqui-
toes (Fig 3D-squares). Plotting the data points as level of DENV versus level of CRVP379,
there is a correlation between expression of CRVP379 in the mosquito midgut and level of
DENV infection in that same midgut (Fig 3E, r = 0.6442, P<0.0001). This indicates that
CRVP379 levels are directly related to levels of DENV infection in the mosquito midgut.
Finally, we repeated the RNAi experiment and allowed the DENV infection to disseminate for
7 days. At day 7 post-infection, whole mosquitoes were homogenized and analyzed for both
CRVP379 expression and DENV infection by qRT-PCR (Fig 3F). The mosquitoes that received
the dsRNA against CRVP379 had a significant reduction in DENV infection levels as com-
pared to the control mosquitoes. This indicates that the reduction of CRVP379 blocks DENV
infection in the whole mosquito.
During DENV infection, CRVP379 interacts with mosquito prohibitin, a
putative DENV receptor
After establishing that DENV requires CRVP379 in both mosquito cells and live Ae. aegypti,
we next wanted to investigate the mechanistic role that CRVP379 plays during infection. To do
this, we used the tandem affinity purification (TAP) assay to identify putative mosquito pro-
teins that bind CRVP379 during DENV infection. We cloned the coding region of CRVP379
into the NTAP vector (Stratagene, CA), which fuses the gene to purification tags, and
Fig 2. DENV infection optimally enhances CRVP379 expression. Aag2 cells were transfected with an insect expression vector encoding CRVP379
(AcCRVP379) or GFP (AcGFP) and A. CRVP379 expression was measured by qRT-PCR at 48 h post-transfection. B. Cells were infected with DENV (MOI
of 1.0) at 48 h post-transfection and infection levels were measure by qRT-PCR at 24 hpi.
doi:10.1371/journal.ppat.1005202.g002
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 7 / 23
transfected this plasmid into Aag2 mosquito cells. Cells were infected with DENV 24h post-
transfection and lysed 24h post-infection. The cell lysate was processed and CRVP379 was
purified using the expressed tags, along with interacting mosquito proteins. The resulting solu-
tion was sent for LC/MS-MS analysis to determine which proteins were pulled out of the
Fig 3. Silencing CRVP379 inhibits DENV acquisition in live mosquitoes. A-E. Mosquitoes were intra-thoracically injected with either dsRNA against the
coding region of CRVP379 or dsRNA against GFP as control. At 4 dpmi, mosquitoes were infected with DENV through blood feeding. At 4 dpi, midgut tissues
were dissected and individually analyzed for gene expression with qRT-PCR analysis. Each data point represents one mosquito midgut. A. Levels of
CRVP379 in select midguts where RNAi was successful, as compared to levels in control mosquitoes. P<0.01. B. Levels of DENV infection in select midguts
where RNAi was successful, as compared to levels in control mosquitoes. P<0.01. Infection rates in midguts where CRVP379 RNAi was successful ranged
from to .000000765–.0000315 ng DENV E/ng actin. C. Levels of CRVP379 in midguts where RNAi was both successful and unsuccessful, as compared to
levels in control mosquitoes. D. Levels of DENV infection in midguts where RNAi was both successful and unsuccessful, as compared to levels in control
mosquitoes. C-D. Squares represent midguts where RNAi did not knock down CRVP379 successfully, cirlces represent midguts where RNAi did knock down
CRVP379 successfully. E. Levels of DENV infection correspond to levels of CRVP379 expression. Both midguts where RNAi did and did not knock down
CRVP379 were analyzed for both CRVP379 expression and DENV infection by qRT-PCR. Data is plotted as ngs of DENV E versus levels of CRVP379,
normalized to mosquito actin. Data correlated with Pearson, r = 0.6442, P<0.0001 F. Silencing CRVP379 reduces DENV infection in whole mosquitoes.
Mosquitoes were intra-thoracically injected with either dsRNA against the coding region of CRVP379 or dsRNA against GFP as control. At 4 dpmi,
mosquitoes were infected with DENV through blood feeding. At 7 dpi, homogenized whole mosquitoes were individually analyzed for gene expression with
qRT-PCR analysis.
doi:10.1371/journal.ppat.1005202.g003
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mosquito cell lysate by CRVP379 during DENV infection. A separate set of cells was trans-
fected with the NTAP vector expressing GFP as control. Table 2 lists the mosquito proteins
that putatively bound CRVP379 and were not identified during control experiments. One of
the proteins identified, prohibitin, was previously characterized as binding to DENV in Aedes
A7 cells [56] and has also been suggested as a putative DENV receptor in mosquito cells [57].
Since we found that prohibitin binds CRVP379 during DENV infection using the TAP assay,
this may indicate that the proteins act together to facilitate DENV entry into mosquito cells.
In establishing prohibitin as a putative receptor in mosquito cells, Kuadkitkan et al used
siRNA against the mosquito prohibitin gene to inhibit protein production and saw a significant
decrease in DENV infection in mosquito cells [57]. To confirm that prohibitin is required for
DENV infection in mosquitoes, we designed dsRNA against the mosquito prohibitin gene and
examined the impact of silencing prohibitin on DENV infection. Ae. aegypti were intra-thorac-
ically inoculated with the dsRNA and at 4 days post micro-injection (dpmi), mosquitoes were
infected with DENV via blood feeding. At 4 days post-infection (dpi), mosquito midguts (MG)
were dissected and analyzed for infection by qRT-PCR analysis. Our results show that DENV
infections levels were greatly inhibited by prohibitin silencing as compared to the control
Table 2. CRVP379 tandem affinity purification assay results.
SeqID Gene Score Expectation
AAEL012282 prohibitin 839 2.10E-80
AAEL003303 hypothetical 212 9.70E-18
AAEL008103 40S ribosomal 450 1.80E-41
AAEL007771 60S ribosomal 353 7.90E-32
AAEL011089 ribonucleoprotein 980 1.80E-94
AAEL001471 hypothetical 357 3.60E-32
AAEL006158 histone H3 152 9.80E-12
AAEL003415 lamin 611 1.30E-57
AAEL011197 actin 1458 0.00E+00
AAEL009883 26S proteasome subunit 276 4.00E-24
AAEL000482 histone H3 214 6.40E-18
AAEL006642 tubulin alpha chain 1350 0
AAEL007609 histone H2A 242 9.60E-21
AAEL008517 elongation factor tu 922 1.10E-88
AAEL015674 histone H2B 913 8.90E-88
AAEL010668 quinone oxioreductase 1276 4.10E-124
AAEL013739 electron transport oxioreductase 372 1.00E-33
AAEL010146 3_H-Coa dehydrogenase 608 2.50E-57
AAEL003530 ribosomal protein P1 288 2.80E-25
AAEL011180 hypothetical 250 1.90E-21
AAEL012736 ribosomal protein L15 344 6.70E-31
AAEL004317 hypothetical 212 1.10E-17
AAEL006511 ubiquitin 213 8.10E-18
AAEL008103 40S ribosomal 450 1.80E-41
AAEL015464 histone H1 339 2.10E-30
AAEL011584 chaperonin 60kD 743 8.60E-71
AAEL010608 succinate dehydrogenase 173 9.10E-14
AAEL004325 ribosomal L5 362 1.10E-32
AAEL008188 60S ribosomal 189 2.00E-15
doi:10.1371/journal.ppat.1005202.t002
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mosquitoes (Fig 4A), confirming a requirement for prohibitin in DENV mosquito infection.
We next performed co-immunoprecipitation to confirm the protein interaction between
CRVP379 and prohibitin. Aag2 cells were transfected with an expression vector coding for
His-tagged CRVP379 protein and/or infected with DENV. Cells were then lysed and antibody
against the His tag was used to pull down His-CRVP379 from the cell lysate. Western blot anal-
ysis identified prohibitin protein in the immunoprecipitate (Fig 4B), demonstrating that His-
tagged CRVP379 bound prohibitin during DENV infection in the mosquito cells. We then
used immunoflourescent imaging to visualize the putative prohibitin-CRVP379 protein inter-
action. Aag2 cells were transfected with the His-tagged CRVP379 expression construct and
infected with DENV 48 hours post-transfection. At 24 hours post-infection, cells were fixed
and stained with antibodies against the His tag and prohibitin protein. Fig 4C shows that the
two proteins were highly colocalized during DENV infection. We next wondered whether pro-
hibitin overexpression could rescue the mosquito cells that were resistant to DENV infection
due to reduced CRVP379 expression. To investigate this, we transfected CRVP379 siRNA into
Fig 4. CRVP379 interacts with mosquito prohibitin during DENV infection. A. Prohibitin is required for DENV infection of Aedes aegypti. Mosquitoes
were intra-thoracically injected with either dsRNA against the coding region of prohibitin (Prohdsrna) or dsRNA against GFP (gfpdsrna) as control. At 4 dpmi,
mosquitoes were infected with DENV through blood feeding. At 4 dpi, midgut tissues were dissected and individually analyzed for gene expression with
qRT-PCR analysis. Each data point represents one mosquito midgut. P<0.01. B. Aag2 cells were transfected with His-tagged CRVP379 and/or infected with
DENV. At 48h post-infection, antibodies against the His tag were used to pull the His-tagged CRVP379 protein out of cell lysates. The precipitated solution
was run on SDS-PAGE gel andWestern blot analysis was performed using antibody against prohibitin. C. CRVP379 and prohibitin co-localize in mosquito
cells during DENV infection. Aag2 cells were transfected with His-tagged CRVP379 and infected with DENV 48h post-transfection. Cells were fixed in 4%
paraformaldehyde 24h post-infection and stained with antibodies against the His-tag (green) and against prohibitin (red). DAPI was used to localize the
nucleus. Representative images are shown.
doi:10.1371/journal.ppat.1005202.g004
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Aag2 cells and then overexpressed mosquito prohitibin before infecting the cells with DENV.
We found that the overexpression of prohibitin did not significantly increase DENV infection
in cells with reduced CRVP379, though there was a slight enhancement (S5 Fig). This indicates
that, though the proteins may act together to facilitate DENV infection in mosquito cells, pro-
hibitin cannot replace the function of CRVP379 protein. Interestingly, the overexpression of
prohibition in control Aag2 cells (with siRNA against GFP) did increase DENV infection
(S5 Fig).
Antisera against CRVP379 inhibits DENV infection in mosquitoes
Since we found that inhibiting CRVP379 gene expression using RNA interference reduced
DENV in Ae. aegypti, we next wanted to try and inhibit protein function with antibody and
examine the effects on DENV infection. To do this, recombinant protein consisting of residues
21–128 of CRVP379 was expressed in E. coli along with a GST tag for purification. To generate
polyclonal antiserum, rabbits were immunized with the recombinant CRVP379 (rCRVP379).
We used the antisera in Western blot analysis to confirm that antibodies would bind the
recombinant protein (Fig 5A). We next ensured that the polyclonal antisera contained antibod-
ies that recognized endogenous CRVP379 protein in the mosquito. To test this, we used the
antisera to stain Aag2 cells and found that there was a strong reaction between the CRVP379
antisera and protein in the cells (Fig 5B). We then used the antisera to probe mosquito midgut
tissue for endogenous protein. Fig 5C demonstrates that the CRVP379 antisera, but not the
pre-immune control sera, recognized protein in the dissected mosquito MG tissue. We also
used the antisera to probe MG tissue with reduced CRVP379 expression due to RNAi (S6 Fig).
To confirm that the antisera did recognize the CRVP379 protein in the mosquito, we ectopi-
cally expressed a His-tagged CRVP379 protein in Aag2 cells and used antibody against the His
tag along with the CRVP379 antisera. Staining with the CRVP379 antisera colocalized with the
anti-His staining, indicating that the antisera recognized the CRVP379 protein (Fig 5D). We
then looked at tissue-specific expression of CRVP379 and found that levels are increased in
both the salivary glands (SG) and midguts (MG) of DENV-infected mosquitoes, as compared
to uninfected mosquito tissues, at all timepoints examined (Fig 5E). We also used ELISA analy-
sis with the CRVP379 antisera using both Aag2 cell lysate, Ae. aegypti salivary gland tissue and
Ae. aegypti saliva to confirm that the antisera bound endogenous CRVP379 protein (Fig 5F).
Next, we tested the effects of the antisera on DENV infection in Aag2 cells. We used two exper-
imental protocols; in one, the antisera was incubated with the cells for 2h at RT and then
infected with DENV (pretreatment group), in the second, antisera and DENV were incubated
for 1h at RT and then added to cells (simultaneous group). We used pre-immune sera for a
control and also did the same experiment in the Huh-7 human liver cell line as an additional
control, as antisera against a mosquito protein should not have an effect on DENV infection in
mammalian cells. Infection was analyzed by qRT-PCR analysis at 24 hpi. We found that the
antisera against CRVP379 inhibited DENV infection in Aag2 cells at dilutions up to 1/100
(Fig 6A). We also found that incubating the antisera with the cells before DENV infection
resulted in a slightly larger reduction in infection levels (Fig 6A). We did not see any reduction
in DENV infection in either experimental group using Huh-7 cells (Fig 6B). We then tested the
effects of the antisera against CRVP379 on DENV infection in Ae. aegypti. Mosquitoes were
fed a mixture of human blood, DENV and either CRVP379 antisera or preimmune sera at 1/
10 and 1/100 dilutions. We also used control antisera against two unrelated, GST-tagged mos-
quito proteins MMP (AAEL003012) and PC (AAEL011045). On 3 dpi, mosquito MG were dis-
sected and qRT-PCR was done to analyze DENV infection. The antisera against CRVP379
significantly reduced the DENV infection in the mosquitoes at both 1/10 and 1/100 dilution as
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compared to mosquitoes which fed on the preimmune sera (Fig 6C). The antisera against the
control GST-tagged proteins did not reduce DENV acquisition in the mosquito MG tested
(Fig 6D).
Discussion
Flaviviruses are known to modify gene expression in their mosquito transmission vectors dur-
ing infection. Our previous results showed that infection of Ae. aegypti with either DENV,
WNV or YFV, modifies expression levels of at least 405 genes [35]. The study of mosquito
genes modified during flavivirus infection may lead to the identification of key vector antiviral
mechanisms as well as key factors for interruption of the viral life cycle. One of the genes that
we identified as being significantly upregulated during DENV infection was the CRVP379
gene. Cysteine-rich venom protein (CRVPs) are members of a large family of cysteine-rich
Fig 5. Antibodies against CRVP379 recognize native protein in Ae. aegypti. A. CRVP379 antisera binds recombinant protein. An SDS-PAGE gel was
run using rCRVP379 andWestern blot analysis was done using the CRVP379 antisera. B. Antibodies were made against mosquito CRVP379 and used to
bind endogenous protein in the Aag2 cell line. Aag2 cells were infected with DENV and cell fixed 24 hpi for staining. A representative image is shown at 20X.
C. CRVP379 antibodies bind endogenous CRVP379 in mosquito midguts. Ae. aegyptiMGwere dissected and fixed in 4% paraformaldehyde before staining.
Both preimmune sera and sera from CRVP-379 injected mice were used for staining (green). Phalloidin594 was used to highlight midgut structure (red). D.
Antisera against CRVP379 recognizes the CRVP379 protein in mosquito cells. Aag2 cells were transfected with an expression construct encoding His-
tagged CRVP379 protein. Cells were fixed 48h post-transfection and stained with both CRVP379 antisera and antibody against the His tag. Secondary
antibodies were used as indicated. E. CRVP379 is increased in both MG and SG of DENV-infected mosquitoes. Mosquitoes were either infected with DENV
or mock solution and organs dissected at 1, 2 and 7 dpi. CRVP379 gene expression was analyzed by qRT-PCR analysis and is shown as ng CRVP379
normalized to actin. DENV was used at 105 PFU/mL for infection in mosquitoes. F. CRVP379 antisera binds mosquito cells and tissues. ELISA analysis was
done with Aag2 cell lysate, Aedes aegypti salivary gland extract (SGE) and Aedes aegypti extracted saliva. O.D. values at 450nm are presented on the
graph.
doi:10.1371/journal.ppat.1005202.g005
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secretory proteins (CRISPs), predominantly found in mammalian males and reptile venom
[58]. CRISPs contain characteristic cysteine rich C-terminal domains thought to act as ion
channel regulators [58] and are also characterized by their role in proteolytic and defense
mechanisms [59]. CRISPs and CRVPs have been described in a broad spectrum of insects and
higher vertebrates [59–62].
Recently, Bonizzoni et al found several CRVP genes to have differentially regulated expres-
sion during DENV infection of Ae. aegypti, including CRVP379, which was shown to be
Fig 6. CRVP379 antisera blocks infection of DENV in mosquitoes. A/B. CRVP379 antisera inhibits DENV infection in mosquito cells. Aag2 (A) or Huh7
(B) cells were either incubated with antisera against CRVP379 or control preimmune sera for 2h at RT and then infected with DENV (pretreatment group) or
antisera against CRVP379 or control preimmune sera was incubated with DENV for 1h at RT and then added to cells (simultaneous group). Infection was
analyzed by qRT-PCR at 24 hpi. C/D. CRVP379 antisera inhibits DENV infection in mosquitoes. Ae. aegyptiwere fed a mixture of blood, DENV and either
CRVP379 antisera or preimmune sera as indicated. Antisera were used at dilutions of 1/10 or 1/100 (C). Infection rates in midguts with CRVP379 antisera
ranged from to .00008785–.07833 ng DENV E/ng actin. A separate group of mosquitoes was fed antisera against control mosquito proteins, MMP and PC
(D). At 3 dpi, mosquito MG were dissected and qRT-PCR analysis done to quantify DENV infection. Results are shown as ng DENV E normalized to
mosquito actin. Each data point represents one MG.
doi:10.1371/journal.ppat.1005202.g006
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upregulated on day 1 and day 14 in the mosquito MG during infection [42]. Here, we found
that CRVP379 was the only CRVP significantly upregulated in mosquitoes after infection with
DENV. Furthermore, knockdown of CRVP379 protein both in vivo and in vitro was able to
reduce viral infection, and we found a significant positive association between the level of
CRVP and DENV infection. This indicates that CRVP379 is specifically required for DENV
infection of Ae. aegypti, at least in our current studies. The genetic variations between both
DENV and mosquito strains likely contributes to differences among various studies, and con-
sistent reporting of these discrepancies warrants further research into these variations along
with additional transcriptomic analysis of the impact of DENV infection on mosquitoes.
Recent work has shown that another mosquito venom protein, a member of the antigen-5
family (Ag5), is upregulated in the salivary glands of Ae. aegypti during Chikungunya virus
infection [63]. This protein is present in the saliva of several insects and is associated with
platelet aggregation inhibition in blood sucking arthropods [46,64]. More investigation is
needed to determine whether mosquito CRVP proteins and the Ag5 proteins are related or
have similar functions during virus infection. Another group of CRVP proteins, the Cysteine-
rich secretory proteins, Antigen 5, and Pathogenesis-related 1 proteins (CAP) superfamily, has
been descried in the sialotranscriptome of Ae. Aegypti as well as in Culex [49,65,66]. Previous
reports indicate that these genes could be preferentially expressed in the salivary glands of
female mosquitos, perhaps suggesting an important role during blood feeding. Our study
showed that up-regulation of CRVP379 occurs in both midgut and salivary glands of mosqui-
toes, and expression in salivary glands increased from day 1 to day 7 during DENV infection.
This suggests that CRVP379 may be found in the saliva of DENV-infected mosquitoes. We
have previously found that Ae. aegypti and certain Anopheles saliva have the ability to induce
an antibody response in humans that can be correlated with the level of exposure to mosquito
bites and disease status [67,68]. Several insect proteins from the CAP superfamily have also
been reported to stimulate mammalian immune responses [69]. Given that CRVP379 has no
homologous proteins in humans, we suspect that it will be a potent immunogen if used as a
TBV.
Many CRVP proteins contain trypsin inhibitor-like (TIL) domains found in members of
the serine protease inhibitor family [70] and functional sequence analysis confirmed that
CRVP379 does contain a TIL domain from amino acids 23–79. Serine proteases and their
inhibitors are known to have very specific interactions, and they play central roles in many cel-
lular processes [71–73]. In addition, both serine proteases and their inhibitors have been
shown to have an impact on DENV infectivity in both mammals and mosquitoes [50,55,74].
As such, we sought to identify the serine protease that CRVP379 potentially bound by using
the TAP assay to investigate which mosquito proteins CRVP379 bound during DENV infec-
tion. We discovered that CRVP379 interacted with a number of mosquito genes during infec-
tion, including histones, ubiquitin and prohibitin.
Previous research has suggested that prohibitin may be a receptor for DENV in mosquitoes,
as expression levels of this protein correlate with the susceptibility of DENV infection in both
Ae. aegypti and Ae. albopictus cell lines [57]. Prohibitin is a protein pervasive expressed and
highly conserved in eukaryotic cells [75] and has been previously described as an inhibitor of
cell proliferation [76]. Prohibitin is found in several cellular compartments including nucleus,
mitochondria and cytoplasm [57]. Furthermore, a recent report shows that Cry4B, one of the
major insecticidal toxins produced by Bacillus thuringiensis israelensis, co-precipitates and co-
localizes with prohibitin in Ae. aegypti larva midgut, and this interaction is able to reduce
DENV infection under physiological conditions [77]. These findings suggest that the inhibition
of proteins that interact with viral receptors may potentially block mosquito infection. Addi-
tionally, several proteins have been reported to bind prohibitin conferring resistance to bacteria
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phagocytosis [78] as well as cell surface expressed binding protein [79]. In DENV infection, it
has been suggested that prohibitin interacts directly at the cell surface with the viral envelope
protein. Our current work shows that CRVP379 is able to interact with several other mosquito
proteins including prohibitin, suggesting that CRVP379 may be involved in virus cell entry
along with other putative roles.
In spite of decades of effort, there are currently no approved DENV vaccines available. A
recent study with a live-attentuated tetravalent DENV vaccine developed by Sanofi Pasteur has
demonstrated partial protection against DENV [22] and shows promising results, though
efforts continue to develop vaccines that will confer full protection. A vector-based vaccine
would nicely complement these efforts at traditional vaccine development and could contribute
as an additional strategy to combat the increasing global spread of DENV. The development of
vaccines targeting either a pathogen or vector protein to prevent transmission to human hosts
is considered essential to the eradication of many emerging tropical diseases, including malaria.
Transmission-blocking vaccines (TBVs) are currently being developed and have been shown to
be successful at preventing malaria infection of Anophelesmosquitoes (12–15). One of these, a
TBV developed against the Plasmodium protein Pfs25, was able to prevent the transmission of
malaria from infected mice to naïve mosquitoes (12,13). Another group found that vaccinating
mice with the mosquito protein serpin-2 prevented the transmission of Plasmodium berghei to
a naïve group of mosquitoes (16). In addition, an arthropod-specific TBV based on the outer
surface protein A (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease, has been
shown to protect mice from spirochete infection (17). Proteins of the sand fly have also been
used successfully as TBVs to prevent the transmission of Leishmania (18).
Dengue virus is transmitted to humans in saliva during mosquito probing and blood feed-
ing. During this process, mosquitoes take in host factors contained in the blood including host
antibodies, complement proteins and immune cells that remain active for several hours post-
feeding [80,81]. Previous studies have shown that the presence of antibodies against mosquito
proteins are able to disrupt mosquito infection and transmission of pathogens [82,83]. This
type of TBV has several advantages over a TBV targeting pathogen antigens, including the abil-
ity to target a conserved molecule among vector genera and that the targeted genes may also
affect mosquito survival in nature. Recently, Cheng et al demonstrated that antibodies against
mosquito C-type lectin proteins were able to block DENV infection in Aedesmosquitoes [34].
Their data strongly suggested that a TBV targeting DENV acquisition in mosquitoes is possible
and may be close at hand. Our results inhibiting DENV in Aedes using antisera targeting
CRVP379 protein showed a similar reduction in viral infection and suggests that CRVP379
may also be a viable target for the development of a TBV. Importantly, CRVP379 has no
homolog in humans and extremely low sequence identity to any protein in the human prote-
ome. This means there should not be any off-target immune reaction targeting self if CRVP379
were to be used to stimulate antibody production in humans.
In the present study, we identified a mosquito protein that was required for DENV infection
in mosquito cells, CRVP379. We showed a correlation between this protein and DENV infec-
tion levels in vitro and in vivo. The interaction between CRVP379 and prohitibin, a putative
viral receptor in mosquitoes, may be the mechanism behind the requirement for infection. In
addition, antiserum against CRVP379 protein was able to significantly inhibit DENV acquisi-
tion in Ae. aegypti. Given that the CRVP379 protein was also upregulated in the mosquito dur-
ing infection with WNV and YFV, it stands to reason that a TBV developed against this
protein may act to block acquisition and transmission of multiple, globally important flavivi-
ruses. We have also been able to detect an antibody response against CRVP379 in human
serum samples, indicating that the protein is immunogenic. We are currently designing studies
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to correlate levels of these antibodies with putative protection against dengue virus infection
and disease severity upon infection.
Materials and Methods
Cell culture and virus growth
The Aag2 Ae. aegypti cell line (ATCC, VA) was used for transfection and infection studies. The
cells were grown at 30°C and 5% CO2 in DMEM supplemented with 10% heat-inactivated fetal
bovine serum (Gemini, CA), 1% penicillin-streptomycin and 1% tryptose phosphate broth
(Sigma, MO). Dengue virus stock was grown in C6/36 Ae. albopictus cell line using the same
media. The dengue strain used was DENV-2 New Guinea C. Cells were infected at an m.o.i. of
1.0, virus was allowed to propagate for 6–8 days, supernatant was removed, spun down and
virus stock was stored at -80°C until use.
RNAi
S1 Fig provides a complete list of the siRNAmolecules used in our in vitro knock-down studies.
Dharmafect4 reagent (Dharmacon,) was used to transfect the siRNA into the Aag2 cells
according to manufacturer’s instrucitons. For gene knockdown in live mosquitoes, dsRNA was
produced from 500bp coding regions of either Ae. aegypti CRVP379, Ae. aegypti prohibitin or
GFP. Briefly, PCR was used to produce a DNA template with T7 overhangs that was then used
with the Ambion Megascript kit to produce the dsRNA molecules. The dsRNA was transfected
into mosquitoes as described.
Mosquito infections
The Rockefeller strain of Ae. aegypti were infected by blood-feeding, using 400 μL of DENV-
infected C6/36 cell supernatant added to 1 mL serum-inactivated human donor blood (The
Blood Center, New Orleans, LA). Mosquitoes were fed for 20 minutes at room temperature
using a hemotek feeder and maintained in groups of 10 at 30°C, 80% humidity. Mosquitoes
were supplied sucrose water as a source of dietary sugar. At the conclusion of experiments,
mosquitoes were briefly washed in 70% ethanol and then rinsed in sterile PBS. Organs were
dissected in sterile PBS and transferred to Eppendorf tubes separately. Mosquito organs were
stored in PBS with protease inhibitors for protein assays and homogenized in RLT buffer (Qia-
gen, CA) for gene expression assays.
qRT-PCR analysis
RNA was isolated from infected Ae. aegyptimosquitoes on Days 1, 2, 7 and purified using
RNeasy kit (Qiagen, CA) according to manufacturer’s instructions. The quantitative RT-PCR
(qRT-PCR) analysis was done using the QuantiFast kit according to manufacturer’s instruc-
tions (Qiagen, CA). Oligos for the qRT-PCR reactions were:
DENV envelope: F: 5’-CATTCCAAGTGAGAATCTCTTTGTCA-3’
R: 5’-CAGATCTCTGATGAATAACCAACG-3’; Ae. aegypti Actin: F: 5’-GAACACCCAG
TCCTGCTGACA-3’, R: 5’-TGCGTCATCTTCTCACGGTTAG-3’
Mosquito transfection
DNA plasmids were injected according to our published whole-body transfection method [84].
Briefly, Cellfectin II (Invitrogen, CA) was mixed with S2 Schneider’s medium at a 1:1 ratio and
then keep at RT for 10 min. Plasmid DNA was combined with this mixture and incubated at
RT for 30 minutes before thoracic microinjection into Aedes aegypti. Mosquitoes were injected
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with 500ng plasmid/300 nL solution. The dsRNA was injected as previously described and as
indicated in the figure legends.
Immunofluorescence analysis
Aag2 Ae. aegypti cells were infected with DENV at an MOI of 0.1. At 24 hours post-infection,
infected cells and control cells were fixed in 4% paraformaldehyde for 20 min at RT, washed
with PBS(-) and then stained for infection using antibodies against CRVP379 (L2 Diagnostics,
CT), DENV envelope gene (Millipore, MA) and/or prohibitin (Abcam, MA). The antibodies
were diluted in 1% BSA at 1/250 and cells were incubated for 20 minutes at RT. Any secondary
antibodies used were standard (anti-mouse or anti-rabbit TRITC and FITC, DAPI and phalloi-
din), and were diluted according to manufacturer’s instructions. Infection was visualized using
fluorescent microscopy, equipment and specifics can be found in figure legends.
TAP expression plasmid constructs
All plasmids were prepared using Qiagen miniprep kits (Valencia, CA) after standard transfor-
mation into DH5α competent bacterial cells. The tagged virus protein nTAP expression plas-
mids were made by cloning the coding regions for each viral protein into the N-terminal TAP
plasmid (Stratagene, CA).
Western blots
Solutions were run on a 4–12% SDS-PAGE gel for 1.5 h at 15 milliamps per gel (unless figure
legend indicates otherwise). The proteins were then transferred to PVDF membrane. The
membrane was blocked with 5% milk in 1% TBST for 1h at RT and then incubated with the
appropriate primary antibody overnight at 4°C. The membrane was washed and then incu-
bated with the appropriate horseradish peroxidase secondary antibody for 1h at RT. The pro-
tein blots were incubated with ECL substrates (Amersham, NJ) for 5 min at RT and then
detected on Kodak film. Antisera production is described below and prohibitin antibody was
purchased from Santa Cruz.
Transfection of plasmids (cells)
The expression plasmids were made from pAc5.1/V5-His A vector (Invitrogen, CA) and clon-
ing was done using PCR along with gene-specific primers as previously described [85]. We
used the Qiagen mini-prep kit to isolate DNA from bacterial cultures after transforming
DH5-alpha cells. Plasmids were transfected into cells using Effectene (Qiagen, CA) according
to manufacturer’s instructions. Briefly, for a 10 cm2 plate, 10 μg of DNA was mixed with
500 μL buffer EC and 32 μL enhancer was added. This was allowed to incubate for 5 min on
the benchtop. Then, 30 μL Effectene reagent was added and the solution vortexed briefly. After
10 min incubation, the solution was added to the cells.
TAP assay
The TAP assay was used to identify mosquito cell proteins that interacted with CRVP379 pro-
tein. All steps were done at 4°C to maintain the protein interactions. The cell or tissue lysates
were applied to streptavidin resin, incubated at 4°C for 2 h, washed, and bound proteins eluted
off. A second purification step was done with calmodulin resin and the proteins were boiled off
into PBS(-). The eluted proteins were analyzed at the Yale University W.M. Keck Foundation
core facility. The eluate was subjected to trypsin digestion followed by LC/MS-MS (liquid chro-
matography and mass spectometry) for peptide sequencing and identification using the
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recently completed Aedes aegyptimosquito genome [47]. Putative mosquito proteins were
identified via amino acid sequence identity to both known mosquito proteins and their mam-
malian counterparts using the BLAST software on the NCBI website. Mosquito proteins found
to bind the tags alone as well as proteins found to bind tagged green fluorescent protein were
eliminated as putative interacting partners.
Protein and antisera production
A recombinant protein consisting of residues 21–128 of CRVP379 was synthetically cloned
into the pGEX-6p-1 expression vector (GE Life Sciences) into the BamH1 and Xho1 sites. The
recombinant plasmid was transformed into Rosetta DE3 pLys2 E. coli cells. GST-CRVP379
protein was purifed from the bacteria cells as inclusion bodies by passing the E coli cells
through a cell disruptor at 20 psi of pressure. Inclusion bodies were used to immunize rabbits
to generate polycolonal antisera (CoCalico Biologicals, Reamstown, PA). Prior to immuniza-
tion, rabbits were bled to obtain pre-immune control sera.
ELISA analysis
Serum samples were coated onto a 96-well ELISA plate (Thermo Fisher Sci, MA) and incu-
bated overnight at 4°C. The plate was blocked with 1% BSA in PBS(-) and incubated with
recombinant CRVP for an hour at RT. The proteins were washed off, antibodies were added
for 30 min at RT, washed off and secondary-HRP was added for 30 min at RT, washed off and
TMB substrate was added for 20 min at RT. Stop solution was added and the O.D. of the wells
was read at 450 nm.
Supporting Information
S1 Fig. List of mosquito genes and siRNA sequences used in RNAi experiments.
(PDF)
S2 Fig. Full results of siRNA screen on DENV infection in mosquito cells.
(PDF)
S3 Fig. Alignment of Ae.aegypti AAEL000374 & AAEL000379.
(PDF)
S4 Fig. Transfection of GFP control in Aag2 cells.
(PDF)
S5 Fig. Effects of Prohibitin overexpression on DENV infection in Aag2 cells with reduced
CRVP379 expression.
(PDF)
S6 Fig. CRVP379 antibody staining in Aedes aegypti midguts with and without CRVP379
RNA intereference.
(PDF)
Acknowledgments
We thank Dr. John F. Anderson and the Connecticut Agricultural Experiment Station (New
Haven, CT) as well as Drs. Patricia Scaraffia and DawnWesson at Tulane University School of
Public Health for mosquito rearing, facility use and experiment insights. We thank the Yale
University Keck Facility proteomics and mass spectrometry resource for their assistance.
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 18 / 23
Author Contributions
Conceived and designed the experiments: BLR MJC TMC. Performed the experiments: BLR
ATMJC DVe ML CMR EC SJ EF TMC. Analyzed the data: BLR AT DVe TMC. Contributed
reagents/materials/analysis tools: DVa SH. Wrote the paper: BLR AT TMC.
References
1. Kao CL, King CC, Chao DY, Wu HL, Chang GJ (2005) Laboratory diagnosis of dengue virus infection:
current and future perspectives in clinical diagnosis and public health. J Microbiol Immunol Infect 38:
5–16. PMID: 15692621
2. Overgaard HJ, Alexander N, Matiz MI, Jaramillo JF, Olano VA, et al. (2012) Diarrhea and dengue con-
trol in rural primary schools in Colombia: study protocol for a randomized controlled trial. Trials 13: 182.
doi: 10.1186/1745-6215-13-182 PMID: 23034084
3. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic
problem in the 21st century. Trends Microbiol 10: 100–103. PMID: 11827812
4. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global
threat. Nat Rev Microbiol 8: S7–16. doi: 10.1038/nrmicro2460 PMID: 21079655
5. Hales S, deWet N, Maindonald J, Woodward A (2002) Potential effect of population and climate
changes on global distribution of dengue fever: an empirical model. Lancet 360: 830–834. PMID:
12243917
6. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62: 71–92. doi:
10.1146/annurev.micro.62.081307.163005 PMID: 18429680
7. Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480–496. PMID:
9665979
8. Gubler DJ, Clark GG (1995) Dengue/dengue hemorrhagic fever: the emergence of a global health prob-
lem. Emerg Infect Dis 1: 55–57. PMID: 8903160
9. Guzman MG, Alvarez M, Halstead SB (2013) Secondary infection as a risk factor for dengue hemor-
rhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent
enhancement of infection. Arch Virol 158: 1445–1459. doi: 10.1007/s00705-013-1645-3 PMID:
23471635
10. van den Berg H, Velayudhan R, Ebol A, Catbagan BH Jr., Turingan R, et al. (2012) Operational effi-
ciency and sustainability of vector control of malaria and dengue: descriptive case studies from the Phil-
ippines. Malar J 11: 269. doi: 10.1186/1475-2875-11-269 PMID: 22873707
11. Jansen CC, Beebe NW (2010) The dengue vector Aedes aegypti: what comes next. Microbes Infect
12: 272–279. doi: 10.1016/j.micinf.2009.12.011 PMID: 20096802
12. Miller M BS, Henderson DA. Control and Eradication. (2006) Disease Control Priorities in Developing
Countries. In: Jamison DT BJ, Measham AR, et al., editors., editor. 2nd edition ed. Washington (DC):
World Bank; 2006. Chapter 62.: Washington (DC): World Bank; 2006. Chapter 62.
13. Pinheiro FP, Corber SJ (1997) Global situation of dengue and dengue haemorrhagic fever, and its
emergence in the Americas. World Health Stat Q 50: 161–169. PMID: 9477544
14. Wilder-Smith A, Macary P (2014) Dengue: challenges for policy makers and vaccine developers. Curr
Infect Dis Rep 16: 404. doi: 10.1007/s11908-014-0404-2 PMID: 24781826
15. Scott RM, Nisalak A, Eckels KH, Tingpalapong M, Harrison VR, et al. (1980) Dengue-2 vaccine: viremia
and immune responses in rhesus monkeys. Infect Immun 27: 181–186. PMID: 6766903
16. Miller BR, Beaty BJ, Aitken TH, Eckels KH, Russell PK (1982) Dengue-2 vaccine: oral infection, trans-
mission, and lack of evidence for reversion in the mosquito, Aedes aegypti. Am J Trop Med Hyg 31:
1232–1237. PMID: 7149108
17. Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, et al. (2000) A dengue virus serotype-1
DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in
Aotus monkeys. Vaccine 18: 3166–3173. PMID: 10856796
18. Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, et al. (1038) Successful
establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 476: 454–
457. doi: 10.1038/nature10356 PMID: 21866160
19. Johnson AJ, Roehrig JT (1999) Newmouse model for dengue virus vaccine testing. J Virol 73: 783–
786. PMID: 9847388
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 19 / 23
20. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, et al. (2000) Recombinant chimeric yellow
fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477–
5485. PMID: 10823852
21. Fink K, Shi PY (2014) Live attenuated vaccine: the first clinically approved dengue vaccine? Expert
Rev Vaccines 13: 185–188. doi: 10.1586/14760584.2014.870888 PMID: 24350687
22. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective effi-
cacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a ran-
domised, controlled phase 2b trial. Lancet 380: 1559–1567. doi: 10.1016/S0140-6736(12)61428-7
PMID: 22975340
23. GuzmanMG, Hermida L, Bernardo L, Ramirez R, Guillen G Domain III of the envelope protein as a den-
gue vaccine target. Expert Rev Vaccines 9: 137–147.
24. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS (1989) Antibody-dependent enhancement of den-
gue virus growth in humanmonocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med
Hyg 40: 444–451. PMID: 2712199
25. Nikin-Beers R, Ciupe SM (2015) The role of antibody in enhancing dengue virus infection. Math Biosci
263: 83–92. doi: 10.1016/j.mbs.2015.02.004 PMID: 25707916
26. Flipse J, Wilschut J, Smit JM (2013) Molecular mechanisms involved in antibody-dependent enhance-
ment of dengue virus infection in humans. Traffic 14: 25–35. doi: 10.1111/tra.12012 PMID: 22998156
27. Burke DS, Kliks S (2006) Antibody-dependent enhancement in dengue virus infections. J Infect Dis
193: 601–603; author reply 603–604.
28. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv
Virus Res 60: 421–467. PMID: 14689700
29. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, et al. (2015) Efficacy of a tetravalent
dengue vaccine in children in Latin America. N Engl J Med 372: 113–123. doi: 10.1056/
NEJMoa1411037 PMID: 25365753
30. Kay BH, Kemp DH (1994) Vaccines against arthropods. Am J Trop Med Hyg 50: 87–96. PMID:
8024089
31. Carter R (2001) Transmission blocking malaria vaccines. Vaccine 19: 2309–2314. PMID: 11257353
32. Coutinho-Abreu IV, Ramalho-Ortigao M (2010) Transmission blocking vaccines to control insect-borne
diseases: a review. Mem Inst Oswaldo Cruz 105: 1–12. PMID: 20209323
33. Wang P, Conrad JT, Shahabuddin M (2001) Localization of midgut-specific protein antigens from
Aedes aegypti (Diptera: Culicidae) using monoclonal antibodies. J Med Entomol 38: 223–230. PMID:
11296827
34. Liu Y, Zhang F, Liu J, Xiao X, Zhang S, et al. (2014) Transmission-blocking antibodies against mosquito
C-type lectins for dengue prevention. PLoS Pathog 10: e1003931. doi: 10.1371/journal.ppat.1003931
PMID: 24550728
35. Colpitts TM, Cox J, Vanlandingham DL, Feitosa FM, Cheng G, et al. (2011) Alterations in the Aedes
aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses. PLoS Pathog
7: e1002189. doi: 10.1371/journal.ppat.1002189 PMID: 21909258
36. Chisenhall DM, Londono BL, Christofferson RC, McCracken MK, Mores CN (2014) Effect of dengue-2
virus infection on protein expression in the salivary glands of Aedes aegypti mosquitoes. Am J Trop
Med Hyg 90: 431–437. doi: 10.4269/ajtmh.13-0412 PMID: 24445208
37. Chisenhall DM, Christofferson RC, McCracken MK, Johnson AM, Londono-Renteria B, et al. (2014)
Infection with dengue-2 virus alters proteins in naturally expectorated saliva of Aedes aegypti mosqui-
toes. Parasit Vectors 7: 252. doi: 10.1186/1756-3305-7-252 PMID: 24886023
38. Baron OL, Ursic-Bedoya RJ, Lowenberger CA, Ocampo CB (2010) Differential gene expression from
midguts of refractory and susceptible lines of the mosquito, Aedes aegypti, infected with Dengue-2
virus. J Insect Sci 10: 41. doi: 10.1673/031.010.4101 PMID: 20572793
39. Behura SK, Gomez-Machorro C, deBruyn B, Lovin DD, Harker BW, et al. (2014) Influence of mosquito
genotype on transcriptional response to dengue virus infection. Funct Integr Genomics 14: 581–589.
doi: 10.1007/s10142-014-0376-1 PMID: 24798794
40. Campbell CL, Harrison T, Hess AM, Ebel GD (2014) MicroRNA levels are modulated in Aedes aegypti
after exposure to Dengue-2. Insect Mol Biol 23: 132–139. doi: 10.1111/imb.12070 PMID: 24237456
41. Zhang M, Zheng X, Wu Y, Gan M, He A, et al. (2013) Differential proteomics of Aedes albopictus sali-
vary gland, midgut and C6/36 cell induced by dengue virus infection. Virology 444: 109–118. doi: 10.
1016/j.virol.2013.06.001 PMID: 23816433
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 20 / 23
42. Bonizzoni M, DunnWA, Campbell CL, Olson KE, Marinotti O, et al. (2012) Complex modulation of the
Aedes aegypti transcriptome in response to dengue virus infection. PLoS One 7: e50512. doi: 10.
1371/journal.pone.0050512 PMID: 23209765
43. Behura SK, Severson DW (2012) Intrinsic features of Aedes aegypti genes affect transcriptional
responsiveness of mosquito genes to dengue virus infection. Infect Genet Evol 12: 1413–1418. doi:
10.1016/j.meegid.2012.04.027 PMID: 22579482
44. Sim S, Ramirez JL, Dimopoulos G (2012) Dengue virus infection of the Aedes aegypti salivary gland
and chemosensory apparatus induces genes that modulate infection and blood-feeding behavior.
PLoS Pathog 8: e1002631. doi: 10.1371/journal.ppat.1002631 PMID: 22479185
45. Dai J, Narasimhan S, Zhang L, Liu L, Wang P, et al. (2010) Tick histamine release factor is critical for
Ixodes scapularis engorgement and transmission of the lyme disease agent. PLoS Pathog 6:
e1001205. doi: 10.1371/journal.ppat.1001205 PMID: 21124826
46. Arca B, Lombardo F, Francischetti IM, Pham VM, Mestres-Simon M, et al. (2007) An insight into the sia-
lome of the adult female mosquito Aedes albopictus. Insect BiochemMol Biol 37: 107–127. PMID:
17244540
47. Nene V, Wortman JR, Lawson D, Haas B, Kodira C, et al. (2007) Genome sequence of Aedes aegypti,
a major arbovirus vector. Science 316: 1718–1723. PMID: 17510324
48. Calvo E, Pham VM, Lombardo F, Arca B, Ribeiro JM (2006) The sialotranscriptome of adult male
Anopheles gambiae mosquitoes. Insect BiochemMol Biol 36: 570–575. PMID: 16835022
49. Ribeiro JM, Charlab R, Pham VM, Garfield M, Valenzuela JG (2004) An insight into the salivary tran-
scriptome and proteome of the adult female mosquito Culex pipiens quinquefasciatus. Insect Biochem
Mol Biol 34: 543–563. PMID: 15147756
50. Conway MJ, Watson AM, Colpitts TM, Dragovic SM, Li Z, et al. (2014) Mosquito saliva serine protease
enhances dissemination of dengue virus into the mammalian host. J Virol 88: 164–175. doi: 10.1128/
JVI.02235-13 PMID: 24131723
51. Furuta T, Murao LA, Lan NT, Huy NT, Huong VT, et al. (2012) Association of mast cell-derived VEGF
and proteases in Dengue shock syndrome. PLoS Negl Trop Dis 6: e1505. doi: 10.1371/journal.pntd.
0001505 PMID: 22363824
52. Bonizzoni M, Britton M, Marinotti O, DunnWA, Fass J, et al. (2013) Probing functional polymorphisms
in the dengue vector, Aedes aegypti. BMCGenomics 14: 739. doi: 10.1186/1471-2164-14-739 PMID:
24168143
53. Gulley MM, Zhang X, Michel K (2013) The roles of serpins in mosquito immunology and physiology. J
Insect Physiol 59: 138–147. doi: 10.1016/j.jinsphys.2012.08.015 PMID: 22960307
54. Xi Z, Ramirez JL, Dimopoulos G (2008) The Aedes aegypti toll pathway controls dengue virus infection.
PLoS Pathog 4: e1000098. doi: 10.1371/journal.ppat.1000098 PMID: 18604274
55. Brackney DE, Foy BD, Olson KE (2008) The effects of midgut serine proteases on dengue virus type 2
infectivity of Aedes aegypti. Am J Trop Med Hyg 79: 267–274. PMID: 18689635
56. Paingankar MS, Gokhale MD, Deobagkar DN (2010) Dengue-2-virus-interacting polypeptides involved
in mosquito cell infection. Arch Virol 155: 1453–1461. doi: 10.1007/s00705-010-0728-7 PMID:
20571839
57. Kuadkitkan A, Wikan N, Fongsaran C, Smith DR (2010) Identification and characterization of prohibitin
as a receptor protein mediating DENV-2 entry into insect cells. Virology 406: 149–161. doi: 10.1016/j.
virol.2010.07.015 PMID: 20674955
58. Gibbs GM, O'BryanMK (2007) Cysteine rich secretory proteins in reproduction and venom. Soc Reprod
Fertil Suppl 65: 261–267. PMID: 17644967
59. Udby L, Calafat J, Sorensen OE, Borregaard N, Kjeldsen L (2002) Identification of human cysteine-rich
secretory protein 3 (CRISP-3) as a matrix protein in a subset of peroxidase-negative granules of neutro-
phils and in the granules of eosinophils. J Leukoc Biol 72: 462–469. PMID: 12223513
60. Parkinson NM, Conyers C, Keen J, MacNicoll A, Smith I, et al. (2004) Towards a comprehensive view
of the primary structure of venom proteins from the parasitoid wasp Pimpla hypochondriaca. Insect Bio-
chemMol Biol 34: 565–571. PMID: 15147757
61. Arensburger P, Megy K, Waterhouse RM, Abrudan J, Amedeo P, et al. (2010) Sequencing of Culex
quinquefasciatus establishes a platform for mosquito comparative genomics. Science 330: 86–88. doi:
10.1126/science.1191864 PMID: 20929810
62. Schambony A, Hefele JA, Gentzel M, Wilm M, Wedlich D (2003) A homologue of cysteine-rich secre-
tory proteins induces premature degradation of vitelline envelopes and hatching of Xenopus laevis
embryos. Mech Dev 120: 937–948. PMID: 12963113
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 21 / 23
63. Tchankouo-Nguetcheu S, Bourguet E, Lenormand P, Rousselle JC, Namane A, et al. (2012) Infection
by chikungunya virus modulates the expression of several proteins in Aedes aegypti salivary glands.
Parasit Vectors 5: 264. doi: 10.1186/1756-3305-5-264 PMID: 23153178
64. Ribeiro JM, Arca B, Lombardo F, Calvo E, Phan VM, et al. (2007) An annotated catalogue of salivary
gland transcripts in the adult female mosquito, Aedes aegypti. BMCGenomics 8: 6. PMID: 17204158
65. Gibbs GM, Roelants K, O'Bryan MK (2008) The CAP superfamily: cysteine-rich secretory proteins, anti-
gen 5, and pathogenesis-related 1 proteins—roles in reproduction, cancer, and immune defense.
Endocr Rev 29: 865–897. doi: 10.1210/er.2008-0032 PMID: 18824526
66. Ribeiro JM, Arca B, Lombardo F, Calvo E, Phan VM, et al. (2007) An annotated catalogue of salivary
gland transcripts in the adult female mosquito, Aedes aegypti. BMCGenomics 8: 6. PMID: 17204158
67. Londono-Renteria B, Cardenas JC, Cardenas LD, Christofferson RC, Chisenhall DM, et al. (2013) Use
of anti-Aedes aegypti salivary extract antibody concentration to correlate risk of vector exposure and
dengue transmission risk in Colombia. PLoS One 8: e81211. doi: 10.1371/journal.pone.0081211
PMID: 24312537
68. Londono-Renteria BL, Eisele TP, Keating J, James MA, Wesson DM (2010) Antibody response against
Anopheles albimanus (Diptera: Culicidae) salivary protein as a measure of mosquito bite exposure in
Haiti. J Med Entomol 47: 1156–1163. PMID: 21175067
69. Ameri M, Wang X, Wilkerson MJ, Kanost MR, Broce AB (2008) An immunoglobulin binding protein
(antigen 5) of the stable fly (Diptera: Muscidae) salivary gland stimulates bovine immune responses. J
Med Entomol 45: 94–101. PMID: 18283948
70. Suzuki M, Itoh T, Anuruddhe BM, Bandaranayake IK, Shirani Ranasinghe JG, et al. (2010) Molecular
diversity in venom proteins of the Russell's viper (Daboia russellii russellii) and the Indian cobra (Naja
naja) in Sri Lanka. Biomed Res 31: 71–81. PMID: 20203422
71. Plotnick MI, Mayne L, Schechter NM, Rubin H (1996) Distortion of the active site of chymotrypsin com-
plexed with a serpin. Biochemistry 35: 7586–7590. PMID: 8652540
72. Wei A, Rubin H, Cooperman BS, Christianson DW (1994) Crystal structure of an uncleaved serpin
reveals the conformation of an inhibitory reactive loop. Nat Struct Biol 1: 251–258. PMID: 7656054
73. Han J, Zhang H, Min G, Kemler D, Hashimoto C (2000) A novel Drosophila serpin that inhibits serine
proteases. FEBS Lett 468: 194–198. PMID: 10692585
74. Rizvi N, Chaturvedi UC, Mathur A (1991) Inhibition of the presentation of dengue virus antigen by mac-
rophages to B cells by serine-protease inhibitors. Int J Exp Pathol 72: 23–29. PMID: 1888663
75. Morrow IC, Parton RG (2005) Flotillins and the PHB domain protein family: rafts, worms and anaes-
thetics. Traffic 6: 725–740. PMID: 16101677
76. McClung JK, Danner DB, Stewart DA, Smith JR, Schneider EL, et al. (1989) Isolation of a cDNA that
hybrid selects antiproliferative mRNA from rat liver. Biochem Biophys Res Commun 164: 1316–1322.
PMID: 2480116
77. Kuadkitkan A, Smith DR, Berry C (2012) Investigation of the Cry4B-prohibitin interaction in Aedes
aegypti cells. Curr Microbiol 65: 446–454. doi: 10.1007/s00284-012-0178-4 PMID: 22767320
78. Sharma A, Qadri A (2004) Vi polysaccharide of Salmonella typhi targets the prohibitin family of mole-
cules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl Acad Sci U S
A 101: 17492–17497. PMID: 15576509
79. Kolonin MG, Saha PK, Chan L, Pasqualini R, ArapW (2004) Reversal of obesity by targeted ablation of
adipose tissue. Nat Med 10: 625–632. PMID: 15133506
80. Grotendorst CA, Carter R (1987) Complement effects of the infectivity of Plasmodium gallinaceum to
Aedes aegypti mosquitoes. II. Changes in sensitivity to complement-like factors during zygote develop-
ment. J Parasitol 73: 980–984. PMID: 3116195
81. Margos G, Navarette S, Butcher G, Davies A, Willers C, et al. (2001) Interaction between host comple-
ment and mosquito-midgut-stage Plasmodium berghei. Infect Immun 69: 5064–5071. PMID:
11447187
82. Chugh M, Adak T, Sehrawat N, Gakhar SK (2011) Effect of anti-mosquito midgut antibodies on devel-
opment of malaria parasite, Plasmodium vivax and fecundity in vector mosquito Anopheles culicifacies
(Diptera: culicidae). Indian J Exp Biol 49: 245–253. PMID: 21614887
83. RamasamyMS, Sands M, Kay BH, Fanning ID, Lawrence GW, et al. (1990) Anti-mosquito antibodies
reduce the susceptibility of Aedes aegypti to arbovirus infection. Med Vet Entomol 4: 49–55. PMID:
1966777
84. Cheng G, Liu L, Wang P, Zhang Y, Zhao YO, et al. (2011) An in vivo transfection approach elucidates a
role for Aedes aegypti thioester-containing proteins in flaviviral infection. PloS one 6: e22786. doi: 10.
1371/journal.pone.0022786 PMID: 21818390
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 22 / 23
85. Colpitts TM, Cox J, Nguyen A, Feitosa F, Krishnan MN, et al. (2011) Use of a tandem affinity purification
assay to detect interactions betweenWest Nile and dengue viral proteins and proteins of the mosquito
vector. Virology 417: 179–187. doi: 10.1016/j.virol.2011.06.002 PMID: 21700306
DENV Requires CRVP for Mosquito Infection
PLOS Pathogens | DOI:10.1371/journal.ppat.1005202 October 22, 2015 23 / 23
